CD274 and non-small cell lung carcinoma: Regarding locally advanced NSCLC, durvalumab currently represents the only FDA-approved and recommended immune checkpoint inhibitor for the treatment of unresectable stage III NSCLC patients, irrespective of histological type and PDL1 expression, whose disease has not progressed after a previous chemoradiotherapy treatment [9].